Overview
OPRX market data
Price History
OPRX price chart
Valuation & Profitability
- P/E (TTM)
- 17.05 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.27 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.04 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.54 – $22.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $116.5 · P/B 1.78 · P/S 1.09.
Company news
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing OfficerGlobenewswire Inc · Jul 23, 2026, 12:15 PM
OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For PhysiciansBenzinga · Jun 30, 2026, 11:40 AM
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning PlatformsGlobenewswire Inc · Jun 25, 2026, 12:15 PM
8-K filing — OptimizeRx Corp (OPRX)SEC EDGAR · Jun 12, 2026, 8:10 PM
OptimizeRx's Electronic Health Record Network Integrated By DeepIntentBenzinga · May 21, 2026, 11:40 AM
Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11Benzinga · May 13, 2026, 8:28 PM
B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10Benzinga · May 13, 2026, 5:41 PM
Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7Benzinga · May 13, 2026, 3:22 PM
OptimizeRx shares are trading lower after the company reported Q1 financial results and cut its FY26 sales guidance below estimates.Benzinga · May 13, 2026, 3:08 PM
Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14Benzinga · May 13, 2026, 1:45 PM